{"prompt": "['Product: MK-3475', '49', 'Protocol/Amendment No.: 604-09', 'Table 6', 'Recommended Chemotherapy Dose Modifications for Hematological Toxicity', 'Drug Related Toxicity', 'Etoposide', 'Cisplatin', 'Carboplatin', 'Dose Level (DL) from Table 3', 'Neutrophils (ANC) <500/mm\u00b3 without fever', 'DL 1', 'DL 1', 'DL 1', 'Febrile neutropenia (fever >38.5\u00b0C and ANC', '<1,000/mm\u00b3)', 'DL -1', 'DL 1', 'DL 1', 'Platelets <50,000/mm\u00b3 without significant bleeding', 'or requiring blood transfusion', 'DL -1', 'DL 1', 'DL 1', 'Platelets <50,000/mm\u00b3 with Grade >2 hemorrhage or', 'requiring blood transfusion', 'DL -2', 'DL -2', 'DL -2', 'Grade 4 hemoglobin', 'DL 1', 'DL 1', 'DL - 1', 'Abbreviations: ANC=absolute neutrophil count, DL=dose level', 'Note: If toxicity can clearly be attributed to one of the drugs, the investigator may choose to only reduce the', 'dose of one of the chemotherapy agents. Investigators may decide to use supportive measures/treatment', 'and/or secondary prophylaxis as per institutional standards (eg, filgrastim, pegfilgrastim, transfusions)', 'instead of dose reductions for the next cycle, if considered in the best interest of the subject.', 'a Should the hematologic toxicity recur, the dose of the agent could be reduced further. However, not more', 'than 2 dose reductions per chemotherapy agent are permitted.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '50', 'Protocol/Amendment No.: 604-09', 'Table 7', 'Recommended Chemotherapy Dose Modifications for Non-hematologic Toxicity', 'Drug Related Toxicity', 'CTCAE Grade', 'Etoposide', 'Cisplatin', 'Carboplatin', 'Dose Level (DL) from Table 3', 'Nausea/vomiting', 'Grade >3b', 'DL 0', 'DL 1', 'DL -1', 'Mucositis', 'Grade >3b', 'DL -1', 'DL - 1', 'DL -1', 'Diarrhea', 'Grade >36', 'DL -1', 'DL 1', 'DL -1', 'Grade 2', 'No modification', 'DL c', 'No modification', 'Peripheral neuropathy', 'Grade 3', 'No modification', 'Discontinued', 'DL 1', 'Grade 4', 'No modification', 'Discontinue', 'DL -1', 'Grade 2', 'DL -2', 'No modification', 'No modification', 'Total bilirubin', 'Grade 3', 'Discontinue', 'No modification', 'No modification', 'Grade 4', 'Discontinue', 'No modification', 'No modification', 'Grade 3', 'DL - 1', 'DL', 'DL -1', 'AST or ALT Elevation', 'Grade 4', 'Discontinue', 'Discontinue', 'Discontinue', 'Other Non-', 'hematologic Toxicity', '(except fatigue and', 'Grade >3', 'DL -1', 'DL -1', 'DL -1', 'transient arthralgia and', 'myalgia)', 'Note: If considered in the best interest of the subject, and consistent with local practice, investigators may', 'decide to use supportive measures/treatment, and/or secondary prophylaxis instead of dose reductions for the', 'next cycle. Also, if toxicity can clearly be attributed to one of the drugs, the investigator may choose to only', 'reduce the dose of one of the chemotherapy agents.', 'a', 'Should the toxicity recur, the dose of the agent could be reduced further. However, not more than 2 dose', 'reductions per chemotherapy agent are permitted.', 'b The first occurrence of Grade >3 nausea/vomiting, mucositis, and diarrhea should be managed', 'symptomatically with optimal medical therapy, and improve to Grade 1 prior to proceeding with additional', 'therapy. Should these events recur despite aggressive management, a dose modification can be employed', 'once the AE improves to Grade 1.', 'c If Grade 2 neurotoxicity recurs after DL -1, drug will be given at DL -2 or switch can be made to the', 'appropriate dose of carboplatin at the discretion of the investigator in consultation with the Sponsor. If', 'Grade 2 neurotoxicity persists after 2 dose level reductions and 21-day hold, switch can be made to the', 'appropriate dose of carboplatin at the discretion of the investigator in consultation with the Sponsor.', 'd If Grade 3 neurotoxicity occurs, cisplatin will be discontinued and, upon improvement, a switch can be', 'made to the appropriate dose of carboplatin at the discretion of the investigator in consultation with the', 'Sponsor.', 'Creatinine clearance:', 'Creatinine clearance (CrCl) will be based on either the Cockcroft-Gault formula', '(Section 5.2.2.2.1) or another acceptable standard formula.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}